DrugPatentWatch Database Preview
Details for Patent: 9,517,220
Email this page to a colleague
» See Plans and PricingWhich drugs does patent 9,517,220 protect, and when does it expire?
Patent 9,517,220 protects PROLENSA and is included in one NDA.
This patent has five patent family members in four countries.
Summary for Patent: 9,517,220
| Title: | Bromfenac bioavailability |
| Abstract: | Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY.TM. formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient. |
| Inventor(s): | Padilla; Angel (Aliso Viejo, CA), Baklayan; George (Huntington Beach, CA) |
| Assignee: | Bausch & Lomb Pharma Holdings Corp. (Rochester, NY) |
| Application Number: | 13/649,271 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,517,220 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 9,517,220
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb | PROLENSA | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 203168-001 | Apr 5, 2013 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,517,220
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2852995 | Start Trial | |||
| European Patent Office | 2765988 | Start Trial | |||
| Mexico | 2014004347 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
